Onsdag 29 Oktober | 11:59:15 Europe / Stockholm

Prenumeration

2025-10-27 14:29:00

Redeye argues that the negative YTD share price performance does not reflect Xvivo’s underlying fundamental developments. We see a doubling potential in the share for this emerging niche leader in the coming 12 months, driven by strengthening sentiment and several near-term catalysts.

Read more and download the Research Update.
 
Follow companies at Redeye to receive the latest equity research within Life Science and Technology.
 
This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/